Sage Therapeutics Net Income
| SAGEDelisted Stock | USD 8.68 0.00 0.00% |
As of the 18th of February 2026, Sage Therapeutics has the Risk Adjusted Performance of 0.0521, coefficient of variation of 1816.42, and Semi Deviation of 1.7. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sage Therapeutics, as well as the relationship between them. Please validate Sage Therapeutics treynor ratio, and the relationship between the variance and potential upside to decide if Sage Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 8.68 per share. Given that Sage Therapeutics has jensen alpha of 0.2621, we advise you to double-check Sage Therapeutics's current market performance to make sure the company can sustain itself at a future point.
Sage Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sage Therapeutics' valuation are provided below:Sage Therapeutics does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Sage |
Search Suggestions
| SA | Seabridge Gold | Company |
| SACH-PA | Sachem Capital Corp | Company |
| SAAEX | Saaex | Mutual Fund |
| SAA | ProShares Ultra SmallCap600 | ETF |
| SAFE | Safe | Cryptocurrency |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Sage Therapeutics reported net income of (400.67 Million). This is 217.4% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 170.17% higher than that of the company.
Sage Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sage Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sage Therapeutics could also be used in its relative valuation, which is a method of valuing Sage Therapeutics by comparing valuation metrics of similar companies.Sage Therapeutics is currently under evaluation in net income category among its peers.
Sage Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.34 | |||
| Operating Margin | (1.71) % | |||
| Current Valuation | 190.79 M | |||
| Shares Outstanding | 62.78 M | |||
| Shares Owned By Insiders | 10.36 % | |||
| Shares Owned By Institutions | 83.59 % | |||
| Number Of Shares Shorted | 2.22 M | |||
| Price To Earning | 3.07 X | |||
| Price To Book | 1.48 X | |||
| Price To Sales | 7.74 X | |||
| Revenue | 41.24 M | |||
| Gross Profit | (75.23 M) | |||
| EBITDA | (409.49 M) | |||
| Net Income | (400.67 M) | |||
| Cash And Equivalents | 1.51 B | |||
| Cash Per Share | 25.47 X | |||
| Total Debt | 11.84 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 17.69 X | |||
| Book Value Per Share | 5.89 X | |||
| Cash Flow From Operations | (267.19 M) | |||
| Short Ratio | 0.65 X | |||
| Earnings Per Share | (4.89) X | |||
| Price To Earnings To Growth | 0.74 X | |||
| Target Price | 8.58 | |||
| Number Of Employees | 353 | |||
| Beta | 0.3 | |||
| Market Capitalization | 544.94 M | |||
| Total Asset | 547.22 M | |||
| Retained Earnings | (2.97 B) | |||
| Working Capital | 459.69 M | |||
| Current Asset | 188.49 M | |||
| Current Liabilities | 15.31 M | |||
| Net Asset | 547.22 M |
About Sage Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sage Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sage Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sage Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Sage Stock
If you are still planning to invest in Sage Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sage Therapeutics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |